Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced that Carole Ben-Maimon, MD, will present at the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021. The event features 1x1 investor meetings and will include a fireside chat on September 9 at 5:00 PM ET. Larimar is focused on developing treatments for complex rare diseases, notably its lead compound CTI-1601 for Friedreich's ataxia, currently in Phase 1 clinical trials in the U.S.

BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in 1x1 investor meetings at the Morgan Stanley 19^th Annual Global Healthcare Conference taking place virtually September 9-15, 2021. Details for the live presentation can be found below.

Presentation Format:	Fireside chat
Date:	Thursday, September 9, 2021
Time:	5:00 PM ET

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

 

FAQ

When is Larimar Therapeutics presenting at the Morgan Stanley Global Healthcare Conference?

Larimar Therapeutics will present on September 9, 2021, at 5:00 PM ET.

What is the format of Larimar's presentation at the conference?

The presentation will be in a fireside chat format.

What is the lead compound of Larimar Therapeutics?

Larimar's lead compound is CTI-1601, being evaluated for Friedreich's ataxia.

What is the main focus of Larimar Therapeutics?

Larimar Therapeutics focuses on developing treatments for complex rare diseases.

What type of company is Larimar Therapeutics?

Larimar Therapeutics is a clinical-stage biotechnology company.